Navigation Links
Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
Date:5/21/2012

lete its review of the lorcaserin NDA resubmission by the PDUFA date; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review or approval; even if any of Arena's drug candidates is approved for marketing, such approval may be subject to limitations on the indicated uses, restricted distribution methods and other limitations; risks related to commercializing new products; unexpected or unfavorable new data; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and its Current Report on Form 8-K filed with the SEC on May 15, 2012. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SEOUL, South Korea , Aug. 28, 2015 /PRNewswire/ ... Chungbuk National University and Dr. Ra from Biostar ... , Confirmed 30% increase of lifespan through multiple ... cognitive function, physical vitality, and life expectancy found ... Researchers in Korea have determined the possibility that adult ...
(Date:8/28/2015)... ANDOVER, Massachusetts and LONDON , ... driven approach seamlessly ... health continuum improving outcomes and ... Philips  (NYSE: PHG AEX: PHIA) today announced its presence ... its latest cardiology solutions, including Heart Model A.I. , EchoNavigator ...
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... QUINCY, Mass., Jan. 24, 2012 Thomson CompuMark ... protection solutions and part of Thomson Reuters, today announced ... new service providing targeted, global trademark intelligence in a ... pharmaceutical brands, which can sometimes lead to prescription errors, ...
... CHARLESTON, S.C., Jan. 24, 2012  Leading age management ... (age management Charleston) and Charlotte (age management ... doses of the hormone DHEA may help sexual function ... yearlong study, published in the December issue of the ...
Cached Medicine Technology:Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 2Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 3Recent Study Reveals Benefits to Women From DHEA Hormone 2
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... On May ... Michigan, joined as sponsor of the “Music With A Mission” benefit concert in Mendon, ... the event was to raise money to support music education programs in the underfunded ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers how this software allows businesses to track product movement from beginning to ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s largest travel ... in Healthcare by Modern Healthcare and will be honored at an awards dinner ... year, the Best Places to Work in Healthcare program recognizes outstanding employers in the ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Dr. Gregory ... such as radiating pain resulting in shoulder pain, hip pain, neck pain, ... in Civil Engineering from the University of Illinois, and then went on to earn ...
(Date:8/28/2015)... Northridge, CA (PRWEB) , ... August 28, 2015 , ... ... special price on Zoom teeth whitening. For just $199, patients can currently receive a ... to traditional in-office teeth whitening procedures, but it includes a number of unique features ...
Breaking Medicine News(10 mins):Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2
... Boards in Quality Measurement &,Improvement, PHILADELPHIA, ... new program for rewarding physicians based on ... Finance Committee has issued,recommendations to the Center ... alternatives for measuring and reporting performance, including,"registry-based" ...
... speech,earlier this week, Wal-Mart Chief Executive Officer Lee ... of offering pharmacy benefit manager,services. In response Bruce ... National Community Pharmacists Association (NCPA) issued the,following statement:, ... reformed. The current PBM business,model is one that ...
... Shaohua Xu, Florida Tech associate professor of biological sciences, has ... has earned a $150,000 grant from Space Florida to test ... Medicine and Occupational Health Branch. , He is also the ... Sciences Laboratory at Kennedy Space Center (KSC) and the research ...
... stem cells that differentiate into bone appears to cause regeneration ... strategy for osteoporosis, according to a report in the February ... by researchers from Massachusetts General Hospital (MGH) and the Harvard ... medication used to treat bone marrow cancer improved bone density ...
... N.J., Jan. 25 inVentiv Health, Inc.,(Nasdaq: ... its Fourth Quarter and,Full Year 2007 results and ... at 9:00 a.m. Eastern Standard Time., Conference ... please dial 800-358-8448 (Domestic) or,706-634-1367 (International). The conference ...
... Health, Inc. (Amex: OPK ),today announced the appointment ... its Board of Directors. The company also announced the,resignation ... to fill the vacancy created by Mr. Eichler,s resignation ... "The addition of Tom Beier and Rick Pfenniger ...
Cached Medicine News:Health News:Senate Finance Committee Recommends Ways That Medicare Can Enhance Current Physician Quality Reporting Initiative (PQRI) 2Health News:NCPA Statement on Wal-Mart's Entry Into the Pharmacy Benefit Market 2Health News:Controversial theory of Alzheimer's origin funded 2Health News:Turning on adult stem cells may help repair bone 2Health News:inVentiv Health to Announce Fourth Quarter and Full Year 2007 Results and Conduct Conference Call on Thursday, February 28th 2Health News:OPKO Health Announces Changes to Board of Directors 2Health News:OPKO Health Announces Changes to Board of Directors 3
Serrated rake tip spatula with 20 gauge shaft. Black finish for reduced glare. Can be used with 20 gauge MVR blades....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 130o....
Double ended with 0.5 mm x 10 mm and 0.5 mm x 15 mm blades. Both blades gently curved. Square serrated handle with polished finish. Most popular size or model....
12 mm angled tip with gently curved blade. Short hexagonal handle with polished finish....
Medicine Products: